Colorectal cancer evolves the way rivers carve stone—slowly, imperceptibly, until the field has already changed. For years it advances without symptoms, a process unfolding in tissue where no alarm sounds. Conf.

dr. Vasile Bintințan, who specializes in oncological colorectal surgery at Regina Maria Cluj Hospital, explains why screening interrupts this silent progression before the disease declares itself through pain or blood. The logic is geological: what you cannot see is already forming.

By the time symptoms appear—blood in the stool, anemia, altered transit—the tumor has often moved beyond early stages. Bintințan advocates for colonoscopic examination after age 40, particularly when alarm signals emerge: blood, mucus, constipation, diarrhea, the sensation of incomplete defecation, or transit disorders that persist without explanation. These signs, he notes, should prompt conversation with a physician and investigation through colonoscopy, which allows both visualization of the colon and collection of biopsies.

Symptoms vary according to location, tumor type, and stage of disease. Tumors in the ascending colon and the first two-thirds of the transverse colon most frequently present through anemic syndrome—fatigue, pallor, the body's quiet distress signals. Those located in the distal third of the transverse colon, descending colon, sigmoid, or rectum manifest differently: transit disorders, predominantly constipation, and colicky pain as the intestine labors to move contents past an obstacle narrowing the lumen.

As disease progresses, this obstruction can become complete, leading to intestinal occlusion. Rectal localizations bring their own signature: blood in stool and a thin, pencil-like appearance of stool, the colon's architecture visibly altered. Colonoscopy remains the diagnostic threshold.

It renders visible what has been hidden, allows tissue to be sampled, transforms suspicion into evidence. Imaging investigations—CT or MRI—follow, mapping the disease's extent, establishing stage. After these investigations, the patient's case moves to a multidisciplinary committee, where specialists convene to analyze findings and determine treatment pathways.

For colon cancer, surgery often initiates treatment. Rectal cancer demands a more layered approach: chemotherapy, radiotherapy, surgical intervention calibrated to the tumor's position in the narrow architecture of the pelvis. Here, robotic surgery has altered what is possible.

Waste piles in Turda prompt urgent calls for action

Fritz faces tough decision on Tomac's government

Bintințan describes its advantages over traditional laparoscopic methods—instrument articulation that mimics the wrist's range of motion, three-dimensional visualization that restores depth perception, a stable operative field, ergonomics that reduce surgeon fatigue during procedures that require sustained precision. The technology scales movements, so a surgeon's hand gesture translates to finer motion at the instrument tip. This matters especially in rectal dissections, where the pelvis is deep and narrow, where millimeters separate successful resection from damage to surrounding structures.

The ability to dissect meticulously, to preserve healthy tissue while removing disease, depends on such precision. Robotic surgery provides it. Yet technology follows detection.

Screening precedes all intervention, all treatment planning, all surgical innovation. It is the first move against a disease that counts on remaining unnoticed. Bintințan returns to this principle: the examination that finds nothing is as valuable as the one that finds something, because it establishes a baseline, because it interrupts the silent years when cancer, if present, is most vulnerable to removal.

The prevalence of colorectal cancer continues to rise, which makes the case for screening not theoretical but immediate. The disease progresses without symptoms until it cannot be ignored, by which point options narrow and outcomes worsen. Colonoscopy after 40, earlier if symptoms appear, represents the point of intervention—the moment when what is hidden can be brought into light and addressed.

Regina Maria Cluj Hospital, where Bintințan practices, offers both the diagnostic tools and the surgical capabilities this disease demands. But the infrastructure matters less than the decision to use it. Screening requires no symptoms, only the understanding that their absence proves nothing.

Blood in stool, anemia, transit changes—these are late signals. The earlier signal is age, family history, the statistical likelihood that somewhere in the colon's long curve, cells may already be dividing incorrectly. Awareness extends beyond individual decisions.

It requires health education that normalizes screening, that treats colonoscopy not as a response to crisis but as routine maintenance, the way one checks a foundation before cracks appear. Communities that adopt this perspective reduce the burden of late-stage diagnosis, shift the population curve toward earlier detection, better outcomes. The fight against colorectal cancer is not waged in operating rooms alone but in the years before surgery becomes necessary, in the consultations that lead to screening, in the colonoscopies performed on patients who feel perfectly well.

Bintințan and his multidisciplinary team represent one end of this continuum—the surgical expertise, the robotic precision, the staging and treatment planning. But the continuum begins earlier, in the decision to look before symptoms force the issue, to treat silence not as reassurance but as the space where disease, if present, is quietly advancing.